SITE MAP   |   CAREERS   |   CONTACT   |   

Prednisporin (FOV1101) is a topical ocular drug candidate that Zalicus has exclusively licensed to Fovea Pharmaceuticals SA, a division of Sanofi, containing low doses of the glucocorticoid, prednisolone acetate and the immunosuppressant cyclosporine A. Fovea has developed a proprietary co-formulation of Prednisporin and is seeking to develop Prednisporin to treat inflammatory ocular diseases such as persistent allergic conjunctivitis. Sanofi has advanced Prednisporin into Phase 2b clinical development in subjects with persistent allergic conjunctivitis. Read More